Private Investigator Licensing California Links

Books

Warning: file_get_contents(http://ecs.amazonaws.com/onca/xml?Service=AWSECommerceService&Version=2005-03-23&Operation=ItemSearch&ContentType=text%2Fxml&SubscriptionId=122CAXMJKCG3B7DHGZG2&AssociateTag=logomilo-20&SearchIndex=Books&BrowseNode=&Keywords=private+investigation+&ItemPage=1&Sort=&ResponseGroup=Images,ItemAttributes,OfferFull,Medium,VariationSummary) [function.file-get-contents]: failed to open stream: HTTP request failed! HTTP/1.1 400 Bad Request in /home/ciceroni/public_html/oi-e.com/includes/amazon.php on line 846

Warning: Invalid argument supplied for foreach() in /home/ciceroni/public_html/oi-e.com/includes/amazon.php on line 868

Private Investigator Licensing California Links

California doctors run afoul of state board but keep working

Press Release

Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada® and TMC278 for ...

Raptor Pharmaceutical Provides Financial and Clinical Program Updates

<< 1 2 3 >>

Private Investigator Licensing California News

California doctors run afoul of state board but keep working

For the people who police California's 100,000 doctors, little is black and white.

Press Release

Gilead Sciences Inc. Posted on:03 Sep 10 Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for marketing approval for the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil (as fumarate)) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse ...

Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada® and TMC278 for ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for marketing approval for the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil (as fumarate)) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase ...

Raptor Pharmaceutical Provides Financial and Clinical Program Updates

Enrollment in Pivotal Phase 3 Clinical Trial in Cystinosis on Schedule for Completion in Q4 2010 with Results Expected Q1 2011